Neurological disorders – including Parkinson’s – are leading source of disability globally
Author: Almaz OhenePublished: 16 November 2017
Prep: Cook: Serves:
New research published this week in the journal ‘JAMA Neurology’ by Professor Bastiaan Bloem, from Radboud University Nijmegen Medical Centre in the Netherlands, and Dr Ray Dorsey from University of Rochester Medical Center, shows that neurological disorders are now the leading source of disability worldwide
The medical community must mobilise to respond to the predicted rapid increase in people living with Parkinson’s over the next twenty years, argue leading Parkinson’s specialists Professor Bastiaan Bloem and Dr Ray Dorsey in a journal article this week.
In an article called ‘Parkinson Pandemic – A Call to Action’ in the journal ‘JAMA Neurology’ earlier this week, the expert physicians point out that between 1990 and 2015, the prevalence of Parkinson’s more than doubled, with an estimated 6.9 million people worldwide living with the condition. They also estimate that by 2040, the number of people with Parkinson’s will increase to 14.2 million as the population ages.
In a bid to combat this growing pandemic, the authors argue that the medical community should pursue the same strategies that transformed HIV from an unknown and fatal illness, into a highly treatable chronic condition.
Dr Ray Dorsey, from the University of Rochester Medical Center, US, said: “Pandemics are usually equated with infectious diseases like Zika, influenza, and HIV – but neurological disorders are now the leading cause of disability in the world and the fastest growing is Parkinson’s disease.”
Their article echoes another study, the ‘Global Burden of Disease’, also co-authored by Dorsey, which appeared in ‘The Lancet Neurology’ in September. That study tracked the prevalence of neurological diseases such as Parkinson’s, Alzheimer’s, stroke, epilepsy, meningitis, encephalitis, multiple sclerosis, and migraine, both globally and by individual country.
Professor Bastiaan Bloem, of the Radboud University NijmegenMedical Centre, the Netherlands, said: “People with HIV infection simply demanded better treatments and successfully rallied for both awareness and new treatments, literally chaining themselves to the doors of pharmaceutical companies. Today, HIV has become a treatable, chronic disease. This upcoming increase in the number of Parkinson’s patients is striking, and frankly, worrisome. We feel it is urgent that people with Parkinson’s go to the pharmaceutical industry and policymakers alike, demanding immediate action to fight this enormous threat.”
Dr Dorsey continued: “For too long Parkinson’s community has been too quiet on these issues. Building on the AIDS community’s motto of ‘silence equals death’, Parkinson’s community should make their voices heard. The current and future burden of this debilitating disease depends upon their action.”
The two academics argue that access to care for Parkinson’s – a highly treatable condition – is also limited. In the US for example, more than 40% of individuals with Parkinson’s over the age of 65 do not see a neurologist, while an online survey of 35 European countries showed that 40% of respondents had never seen a Parkinson’s specialist. In less wealthy nations, many are never diagnosed. In a door-to-door study in Bolivia, none of the individuals found to have the condition had ever been diagnosed or received treatment.
Todd Sherer, CEO of The Michael J Fox Foundation, said: “Too many people have Parkinson’s today and more will face diagnoses tomorrow. We all – government, patient organisations, researchers, doctors and patients – must work together for better care for those living with this disease and research toward a future without Parkinson’s.”
Dr Ray Dorsey Dr Ray Dorsey is David M Levy professor of neurology and director of the Center for Health and Technology at the University of Rochester Medical Center, US, where he is helping investigate new treatments for movement disorders and improve the way care is delivered for people with Parkinson and other neurological disorders.
Dr Dorsey previously directed the movement disorders division and neurology telemedicine at Johns Hopkins, Maryland, US. Dr Dorsey’s research has been published in the leading medical, neurology, and economic journals and has been featured in The New York Times, and The Wall Street Journal.
Image credit: University of Rochester Medical Center
Professor Bastiaan Bloem Baastian Bloem is a consultant neurologist at the Department of Neurology, Radboud University Nijmegen Medical Centre, the Netherlands. In 1994, he obtained his PhD degree at the Leiden University Medical Centre, the Netherlands. In 2002, he founded and became medical director of Parkinson Centre Nijmegen (ParC), the Netherlands, which was recognised from 2005 onwards as centre of excellence for Parkinson’s disease.
Together with Dr Marten Munneke, he also developed ParkinsonNet, where people with Parkinson’s “co-design” their treatment programme in collaboration with a dedicated, multi-disciplinary team – accessed via ParkinsonNet’s online database of expert practitioners.
‘Back To The Future’ sneakers to raise millions for Parkinson’s research
Nike will donate money raised from new limited edition sneakers
6 days ago
Is dry eye disease common in people with Parkinson’s?
Dry eye disease can involve symptoms such as a lower blinking rate and typically occurs when the eyes are not effectively moistened by tears – leading to discomfort and possible vision loss. Now, a recent study from Japan has investigated the previously underexplored relationship between dry eye disease and Parkinson’s. As part of their research, the team analysed 13 studies published between 2004 and 2022, which involved more than 1,500 people with Parkinson’s. Five of the reports highlighted the prevalence of dry eye disease in people with the condition – with 61% experiencing symptoms. “Our findings emphasize the need for clinicians to be vigilant of the presence of dry eye disease when managing [people with Parkinson’s],” the researchers wrote. However, they noted that more research is needed – especially “future large-scale studies” – to help understand the relationship between dry eye disease and the condition.
Highlighting dental care needs among people with Parkinson’s disease
Researchers from the University of Copenhagen, Denmark, have published a new study looking into dental care among people with Parkinson’s. Using a national register to obtain data relating to dental care between 2015 and 2019, the team identified 6,874 people with Parkinson’s, whose data was then compared to a control group of 34,285 people without the condition. A key takeaway from the five-year study was that a larger portion of people with Parkinson’s were not regular users of the dental care system – 21%, compared to 16.9% in the control group. The findings published in the journal ‘Community Dentistry and Oral Epidemiology’ also revealed that people with Parkinson’s utilised more dental-related treatment services than those in the control group – such as fillings and extractions. The researchers concluded: “This knowledge can be used by clinicians and decision-makers to ensure the optimal dental care for persons with Parkinson’s.”
Could risk factors for Parkinson’s disease be “largely man-made”?
New research has highlighted evidence of a potential link between Parkinson’s risk and exposure to toxic environmental factors – including air pollutants and human-made materials. The research was presented at the 147th Annual Meeting of the American Neurological Association in Chicago, US, as part of a symposium on neurological disorders. The evidence included a study that highlighted that exposure to toxic pollutants may activate genes associated with the condition and that current environmental policies fail to consider the potential long-term effects of neurotoxic chemicals. “The world’s fastest-growing brain disease is largely man-made,” said neurologist Dr Ray Dorsey, one of the symposium speakers, in a press release. “The principal causes are toxic exposures to chemicals synthesised in the labs of chemical companies.” Calling for greater awareness surrounding the issue, he said: “If we educate the communities we’re supposed to serve, we can have them be mobilised and change the course of…